Green and sensitive spectrofluorometric methods have been developed and validated for the determination of timolol maleate (TML)/hydrochlorothiazide (HCT) and amiloride hydrochloride (AMH)/hydrochlorothiazide in tablets. The proposed spectrofluorometric procedures were found to be linear in the range of 4-12, 5-35 and 0.025-0.2 mg L -1 for HCT, TML and AMH, resp. The excitation and emission wavelengths for HCT, TML and AMH at room temperature were 270 and 375, 295 and 435, 330 and 415 nm, resp. The methods were validated with respect to ICH guidelines. The AMH showed higher sensitivity with lower values of LOD and LOQ values compared to HCT and TML. The proposed methods were applied to two pharmaceutical formulations; the method for HCT and AMH has proven as reliable assaying method, whereas the method for TML, when combined with HCT, is applicable to screening semiquantitative analyses.
Timolide is supplied as tablets containing timolol maleate (TML) and HCT. TML is (2S)-1-[(1,1-dimethyl-ethyl)amino]-3-[[4-(morpholin-4-yl)-1,2,5-thiadiazol-3-yl] oxy] propan-2-ol (Z)-butenedioate. It has a molecular formula C 13 H 24 N 4 O 3 S × C 4 H 4 O 4 with a molar mass of 432.49. TML is a non-cardioselective beta-blocker; it is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. It is also an active treatment for hypertension, angina pectoris and myocardial infarction (3) (4) (5) .
In recent years, increasing attention has been focused on the simultaneous determination of binary mixture of AMH/HCT. Sophisticated instrumentation and techniques were applied for the quantitative analysis. Availability of apparatus, high-cost organic solvents and high cost of such analyses limited their routine use. Some of these techniques are spectrophotometric absorbance ratio method (6) , ratio spectra derivative spectrophotometry coupled HPLC (7, 8) , differential pulse polarography coupled with partial least squares (9) , and the reversed-phase HPLC method (10) (11) (12) .
Few analytical techniques have been reported for the analysis of HCT and TML combinations, for example, derivative and derivative-ratio spectrophotometry (8) and the flowinjection method (13) .
Analysis of AMH and HCT combinations and, even more, in the combination with TML or another component was reported (6, 7) . Chemometric procedures such as classical least squares (CLS), principal components regression (PCR) and partial least squares were successfully applied for the analysis of synthetic samples and commercial tablet preparations containing AMH and HCT alone, or containing AMH, HCT in association with ate nolol (ATL) or TML (6) . Moreover, analysis of combinations of three components, AMH, HCT and ATL in combined formulations was carried out using derivative spectroscopy (7) .
This work was intended to demonstrate the analysis of the aforementioned analytes in combined formulations in the aqueous medium, to meet the requirements of green chemistry (14) . It was devoted to the application and development of spectrofluorometric method for the analysis of AMH/HCT and TML/HCT in synthetic samples and marketed formulations.
EXPERIMENTAL

Apparatus
Perkin Elmer LS45 Fluorescence Spectrometer was used for fluorescence measurements using a 1-cm quartz cuvette, part number B0631107 (Perkin Elmer, USA). The data analyses were carried out using a Flwinlab software, version 4.00.03. All measurements were carried out at 22 ± 2 °C.
Materials
The HCT (purity 99.2 %) was purchased from Unichem Laboratories Limited, India. AMH was supplied by Bal Pharma Limited, India (purity 99 %). TML was supplied by Supriya Lifescience Ltd., India (purity 99 %). Magnesium stearate (Sigma-Aldrich, USA), povidone (VWR, USA), lactose (VWR), corn starch (Avonchem Limited, UK), colloidal silicon dioxide (Sigma-Aldrich), cellulose (Fisher Scientific SAS, France), Insacoat II IA-30103 colorant (United Pharmaceuticals, Jordan), FD&C Blue 2 colorant (Hikma Pharmaceuticals, Jordan) were used to prepare placebo powder.
Commercial tablets Uniretic ® -amiloride hydrochloride (5 mg) and hydrochlorothiazide (50 mg) (United Pharmaceuticals, Jordan) and Timolide ® -timolol maleate (10 mg) and hydrochlorothiazide (25 mg) (Merck Inc., USA), were analyzed. The Uniretic excipients provided by the manufacturer were: povidone, lactose, corn starch, colloidal silicon dioxide, Insacoat II IA-30103 colorant and magnesium stearate. Timolide ® excipients were cellulose, starch, magnesium stearate and FD&C Blue 2 colorant.
Standard solutions
Standard stock solutions. -HCT, AMH, and TML stock solutions were prepared from 100 mg of pure powder of each compound, accurately weighed, and transferred into a 500-mL volumetric flask containing 1.0 mL ethanol. The solution was shaken well and thereafter diluted to the mark with distilled water. The stock solutions (200 mg L -1 ) were protected from light and kept at room temperature.
Validation of spectrofluorometric methods
Validation of the analytical methods was performed with respect to linearity, the limit of detection and quantitation, accuracy and precision, specificity and robustness, according to the ICH guidelines (15).
Linearity. -It was evaluated by analyzing five-level standard solutions for HCH, AMH, and TML in triplicate. Under the best experimental conditions, linear relationships between fluorescence intensity and concentration were achieved.
Limits of detection and quantitation (LOD&LOQ)
. -LOD is defined as 3.3σ/s, where σ is the standard deviation of replicate determinations of a blank, s is the slope of the regression line, while LOQ is defined as 10σ/s. Accuracy and precision. -The model accuracy was evaluated by applying the proposed methods to the determination of three different concentrations of HCT (5, 7 and 11 mg L -1 ), AMH (0.030, 0.12 and 0.18 mg L -1 ) and TML (6, 16 and 24 mg L -1 ) (5 replicates). The determination of standard HCT, AMH and TML were carried out on the same day and for three consecutive days to test the repeatability and intermediate precision of the proposed methods.
Specificity. -It was achieved with the analysis of ten synthetic mixtures of HCT/AMH and HCT/TML. The ratios of the training set mixtures were selected randomly with two mixtures (mixture 3: 10:1, m/m, HCT/AMH, and mixture 9:2:1, m/m, HCT/TML) reproducing the composition of the commercial tablets (Uniretic ® and Timolide ® ). To ensure that these mixtures are mimicking the real samples, the prepared solutions were mixed with placebo powder (1 mL in 0.1 g powder), vortexed, stored for 10 minutes at 4 °C and then filtered (0.2-μm pore size).
Emission spectra of HCT, AMH, and TML were partially overlapping in the region between 350 and 480 nm. A background subtraction approach was utilized to resolve this overlapping. This approach was applied to extract fluorescence spectra from Raman fluorescence in the case when the samples exhibited both fluorescence and Raman (16, 17) .
In this case, it is necessary to neglect the effect of the internal absorption of one compound from the emission of the second compound. In the analysis of mixture 1 that contained HCT and AMH, emission of AMH was considered as background for the emission spectra of HCT/AMH solution. To fulfill such consideration, the fluorescence spectrum for AMH with concentration exactly equal to that in the mixture was recorded and stored as a background. The background subtraction facility in the software was used to extract the fluorescence of HCT from the emission of the mixture. A similar approach was used to evaluate the concentration of AMH in the mixture solution.
Robustness. -It was evaluated by studying the influence of small variations of the method conditions. These parameters include a variation of the excitation wavelength by ± 2 nm, the solution temperature by ± 5 °C, and emission wavelength by ± 2 nm. Three concentrations (5, 7, 11 mg L -1 ) of standard HCT, (0.030, 0.12, 0.18 mg L -1 ) of standard AMH, and (6, 16, 24 mg L -1 ) of standard TML were analyzed and evaluated, and one parameter was changed at a time.
Commercial tablets analysis
Stock and working solutions of market samples were prepared by pounding 20 tablets of each formulation to a powder. An accurately weighed amount (1.8843 g) of Uniretic ® was transferred into a 250-mL volumetric flask containing 10 % aqueous ethanol. The solution was then sonicated for a few minutes and filtered using a 0.20-μm Whatman filter paper to remove insoluble components to get 215 mg L -1 HCT and 1076 mg L -1 AMH (as stock). An appropriate aliquot (0.60 mL) from the stock was transferred to a 25-mL volumetric flask to prepare 5.2 mg L -1 HCT and 25.8 mg L -1 AMH.
The stock and working solutions of Timolide ® were prepared as previously described for Uniretic ® . The stock solution was prepared by dissolving 0.4233 g of Timolide ® powder in water. HCT and TMT were 10.8 mg L -1 and 24.7 mg L -1 , resp., in water, after dilution.
The concentration of HCT, AMH and TMT in laboratory prepared mixtures and commercial preparations were calculated using the parameters of the linear regression of each combination (Table I) .
RESULTS AND DISCUSSION
Absorption and fluorescence spectra
Spectra of HCT, TML and AMH were separately recorded using water as a blank (see Fig. 1 ). Fig. 1 shows that absorption peaks of HCT were at 225, 270 and 316 nm with molar absorptivity of 3.45 × 10 4 , 1.78 × 10 4 and 2.91 × 10 3 L mol -1 cm -1 , resp., of TML at 207 and 295 nm with molar absorptivity of 1.56 × 10 4 and 8.58 × 10 3 L mol -1 cm -1 , resp., and of AMH at 210, 285 and 365 nm with molar absorptivity of 8.80 × 10 4 , 1.26 × 10 4 and 1.55 × 10 4 L mol -1 cm -1 , resp.
The quantitative analyses of HCT, TML and AMH in artificial mixtures and binary pharmaceutical formulations as HCT/TML and HCT/AMH were based on the direct measurements of their fluorescence. HCT, TML and AMH exhibited maximum fluorescence at λ em of 375 nm for HCT, 435 nm for TML and 415 nm for AMH after excitation at λ ex of 270, 295 and 330 nm for HCT, TML and AMH, resp. (see Fig. 2 ). The fluorescence of these compounds was greatly influenced by drug excipients which decreased the compounds' quantum yields (increased rates of radiationless decay) resulting in low sensitivity of detection. To minimize the influence of common excipients on fluorescence intensities of target compounds, filtration and spectral data manipulation were carried out. Table I ).
Validation of the spectrofluorometric methods
Limits of detection and quantitation.
-The calculated limits of detection for HCT, AMH, and TML were 0.0104, 0.0013 and 0.070 mg L -1 , resp. (Table I) .
Accuracy and precision. -The model average percent recoveries ranged 99.9-100.4, 99.4-100.3 and 99.0-100.3 % for HCT, AMH and TML, resp. The observed bias in the accuracy was acceptable since it was within the margin of errors. Thus, an adequate accuracy of the model was achieved. The precision of the method was judged by performing intra-day and inter-day analysis. The repeatability RSD was 0.6, 0.4 and 0.6 % for HCT, AMH and TML, resp. The intermediate precisions RSD was 0.7, 0.7 and 0.8 % for HCT, AMH and TML, resp. The RSDs below 1 % indicated reasonable repeatability and intermediate precision. The results are summarized in Table II .
Specificity. -The specificity of the developed method was performed on HCT/AMH and HCT/TML combinations in synthetic mixtures with added excipients, simulating the composition of drug formulations Uniretic ® and Timolide ® . The emission spectra of synthetic mixtures displayed in Table III are presented in Figs. 3 and 4 . Since emission spectra of HCT, AMH, and TML were partially overlapping in the region between 350 and 480 nm, background subtraction approach was utilized. For example, in the analysis of mixture 1 which contained HCT and AMH (see Table III ), emission of AMH or HCT was set as a background for the emission spectra of HCT/AMH mixture solution to extract emission of the other component (mixture 1: A and B, resp., Fig. 3 ).
The analysis of the synthetic mixtures showed acceptable mean recoveries of 97.8 ± 1.6, 98.5 ± 0.5 and 97.1 ± 1.0 % for HCT, AMH and TML, resp. Moreover, the specificity was also evaluated regarding possible spectral interferences from the excipients. The emission spectra of commercial tablets solutions did not show any additional peaks when compared to the emission of synthetic mixtures. The concentration of each individual component in the synthetic mixtures was calculated from the regression equation of the calibration curve (see Table III ).
Robustness. -The solutions were solely prepared in water. The pH of the spiked solutions (standards and mixtures) was above 7, the solution acidity was not modified at any condition to ensure the integrity of the active ingredients. Changing the solution composition by adding organic solvent or inorganic salts was completely excluded to ensure method greenness.
Small changes to the method conditions, including temperature, and excitation and emission wavelength, did not affect the recovery of the drugs. Recoveries ranged 97.8-101.6 % and RSDs were 0.2-1.8 %, which indicated that the method was robust enough (see Table IV ). a HCT (n = 5), three concentrations (5,7,11 mg L -1 ), excitation and emission were 270 and 375 nm, resp. b AMH (n = 5), three concentrations (0.030, 0.12, 0.18 mg L -1 ), excitation and emission were 330 and 415 nm, resp. c TML (n = 5), three concentrations (6, 16, 24 mg L -1 ), excitation and emission were 295 and 435 nm, resp. d The ambient temperature was 22 °C. This work 0.070 Fluorescence Spectrofluorometry a RP C 18 base deactivated silica column with a mobile phase consisting of triethylamine (pH 3.0) adjusted with orthophosphoric acid and acetonitrile, the flow rate of 1.4 mL min -1 ; b Generation of ratio spectra of two-drug combinations, candesartan cilexetil and HCT. HCT was estimated using the amplitudes between 251 and 276 nm; c RP-HPLC using a Shim-pack C 18 column at a flow rate of 1 mL min -1 . The mobile phase consisted of water and acetonitrile in the ratio of 35:65, using a UV detector at 281 nm; d Sorption of amiloride on a cation-exchange resin at pH 4.0 and direct measurement of its intrinsic UV absorbance in the solid phase at 362 nm and 412 nm; e BDS Hypersil phenyl column and a mobile phase consisting of acetonitrile and 25 mmol L -1 phosphate buffer, pH 4.0 (50:50, V/V), 1.2 mL min -1 , UV detection at 210 nm; f Derivative spectrophotometry using the zero-crossing measurements. Linear calibration graphs of first-derivative values at 250.3 nm for dorzolamide hydrochloride and 315.8 nm for TML.
